ROIV Roivant Sciences Ltd.
Nasdaq · SEC CIK 1635088 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $897.02M 47 sales by 12 insiders
- Filings on record
- 427 since 2021-10-22, latest 2026-09-22 21:00
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| MANCHESTER KEITH S | Dir | — | $154.47M |
| Gold Daniel Allen | Dir | — | $147.38M |
| QVT Financial LP | Dir by Deputization | — | $147.38M |
| Sukhatme Mayukh | Pres, CIO, Dir | — | $109.13M |
| Ramaswamy Vivek | 10% | — | $105.88M |
| Venker Eric | Pres, Immunovant CEO | — | $89.77M |
| Torti Frank | Pres, Vant COB | — | $82.04M |
| Gline Matthew | CEO, Dir | — | $46.17M |
| Pulik Richard | CFO | — | $9.12M |
| Fitzgerald Meghan | Dir | — | $3.27M |
Transactions 563
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-22 21:00 | 2026-09-20 | ROIV | Humes Jennifer | CAO | F - Tax | $39.77 | -3,880 | 106.4K | -4% | -$154.3K | |
| 2026-09-22 18:26 | 2026-09-20 | ROIV | Pulik Richard | CFO | F - Tax | $39.77 | -2,129 | 269.7K | -0.8% | -$84.7K | |
| D | 2026-09-18 21:00 | 2026-09-16 | ROIV | MANCHESTER KEITH S | Dir | A - Grant | $0.00 | +5,054 | 1.75M | +0.3% | $0 |
| D | 2026-09-18 19:12 | 2026-09-16 | ROIV | Gold Daniel Allen | Dir | A - Grant | $0.00 | +5,054 | 8.97M | +0.1% | $0 |
| D | 2026-09-18 19:06 | 2026-09-16 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +5,054 | 123.7K | +4% | $0 |
| D | 2026-09-18 19:01 | 2026-09-16 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +5,054 | 112.0K | +5% | $0 |
| D | 2026-09-18 18:57 | 2026-09-16 | ROIV | Fitzgerald Meghan | Dir | A - Grant | $0.00 | +5,054 | 41.2K | +14% | $0 |
| D | 2026-09-18 18:56 | 2026-09-16 | ROIV | Epperly Melissa B, | Dir | A - Grant | $0.00 | +5,054 | 15.0K | +51% | $0 |
| MT | 2026-09-17 18:43 | 2026-09-15 | ROIV | Epperly Melissa B, | Dir | S - Sale | $39.74 | -4,938 | 9,900 | -33% | -$196.2K |
| MT | 2026-09-17 18:42 | 2026-09-15 | ROIV | Fitzgerald Meghan | Dir | S - Sale | $39.74 | -5,112 | 36.1K | -12% | -$203.2K |
| 2026-09-14 21:00 | 2026-09-10 | ROIV | Gold Daniel Allen | Dir | F - Tax | $40.94 | -5,133 | 8.96M | -0.1% | -$210.1K | |
| 2026-09-14 18:42 | 2026-09-10 | ROIV | Oren Ilan | Dir | F - Tax | $40.94 | -2,378 | 118.6K | -2% | -$97.4K | |
| 2026-09-14 18:34 | 2026-09-10 | ROIV | Epperly Melissa B, | Dir | F - Tax | $40.94 | -2,179 | 14.8K | -13% | -$89.2K | |
| 2026-09-14 18:29 | 2026-09-10 | ROIV | Fitzgerald Meghan | Dir | F - Tax | $40.94 | -1,743 | 41.2K | -4% | -$71.4K | |
| 2026-09-14 18:25 | 2026-09-10 | ROIV | MOMTAZEE JAMES C | Dir | F - Tax | $40.94 | -2,905 | 106.9K | -3% | -$118.9K | |
| DT | 2026-09-10 21:00 | 2026-09-08 | ROIV | Fitzgerald Meghan | Dir | M - OptEx | $8.80 | +20.0K | 63.0K | +47% | +$176.0K |
| DT | 2026-09-10 21:00 | 2026-09-08 | ROIV | Fitzgerald Meghan | Dir | S - Sale+OE | $39.90 | -20.0K | 43.0K | -32% | -$798.0K |
| DT | 2026-09-01 21:00 | 2026-08-28 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.80M | +13% | +$770.0K |
| DMT | 2026-09-01 21:00 | 2026-08-28 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $35.77 | -200.0K | 1.60M | -11% | -$7.15M |
| 2026-08-24 21:00 | 2026-08-20 | ROIV | Pulik Richard | CFO | F - Tax | $36.84 | -5,749 | 271.8K | -2% | -$211.8K | |
| 2026-08-24 21:00 | 2026-08-20 | ROIV | Venker Eric | Pres, Immunovant CEO | F - Tax | $36.84 | -13.9K | 1.60M | -0.9% | -$512.4K | |
| DM | 2026-08-21 21:00 | 2026-08-19+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $3.85 | +335.2K | 18.78M | +2% | +$1.29M |
| DM | 2026-08-21 21:00 | 2026-08-19+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $36.88 | -335.2K | 18.63M | -2% | -$12.36M |
| DM | 2026-08-18 21:00 | 2026-08-14+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $3.85 | +664.8K | 18.66M | +4% | +$2.56M |
| DM | 2026-08-18 21:00 | 2026-08-14+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $36.34 | -664.8K | 18.63M | -3% | -$24.16M |
| DT | 2026-07-29 21:00 | 2026-07-27 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.81M | +12% | +$770.0K |
| DT | 2026-07-29 21:00 | 2026-07-27 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $34.95 | -200.0K | 1.61M | -11% | -$6.99M |
| 2026-07-21 21:00 | 2026-07-17 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +405 | 109.8K | +0.4% | $0 | |
| 2026-07-21 21:00 | 2026-07-17 | ROIV | Epperly Melissa B, | Dir | A - Grant | $0.00 | +543 | 17.0K | +3% | $0 | |
| 2026-07-21 21:00 | 2026-07-17 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +775 | 121.0K | +0.6% | $0 | |
| 2026-07-02 19:06 | 2026-06-30 | ROIV | Gline Matthew | CEO, Dir | F - Tax | $35.39 | -76.2K | 16.66M | -0.5% | -$2.70M | |
| DT | 2026-07-02 19:03 | 2026-06-30 | ROIV | Fitzgerald Meghan | Dir | M - OptEx | $8.80 | +10.0K | 53.0K | +23% | +$88.0K |
| DT | 2026-07-02 19:03 | 2026-06-30 | ROIV | Fitzgerald Meghan | Dir | S - Sale+OE | $34.90 | -10.0K | 43.0K | -19% | -$349.0K |
| 2026-07-02 19:01 | 2026-06-30 | ROIV | Torti Frank | Pres, Vant COB | F - Tax | $35.39 | -40.3K | 13.54M | -0.3% | -$1.43M | |
| 2026-07-02 19:00 | 2026-06-30 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | F - Tax | $35.39 | -46.9K | 18.63M | -0.3% | -$1.66M | |
| DT | 2026-07-01 18:34 | 2026-06-29 | ROIV | Epperly Melissa B, | Dir | M - OptEx | $4.46 | +17.8K | 34.2K | +108% | +$79.2K |
| DMT | 2026-07-01 18:34 | 2026-06-29 | ROIV | Epperly Melissa B, | Dir | S - Sale+OE | $34.38 | -17.8K | 16.5K | -52% | -$610.3K |
| MI | 2026-06-30 20:38 | 2026-06-26+ | ROIV | MANCHESTER KEITH S | Dir | S - Sale | $34.32 | -1.44M | 13.69M | -10% | -$49.35M |
| 2026-06-30 20:38 | 2026-06-30 | ROIV | MANCHESTER KEITH S | Dir | S - Sale | $35.45 | -200.0K | 1.75M | -10% | -$7.09M | |
| MI | 2026-06-30 20:30 | 2026-06-26+ | ROIV | Gold Daniel Allen | Dir | S - Sale | $34.32 | -1.44M | 13.69M | -10% | -$49.35M |
| MI | 2026-06-30 19:59 | 2026-06-26+ | ROIV | QVT Financial LP | Dir by Deputization | S - Sale | $34.32 | -1.44M | 13.69M | -10% | -$49.35M |
| DM | 2026-06-29 18:23 | 2026-06-25+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $3.85 | +1.00M | 19.18M | +6% | +$3.85M |
| DM | 2026-06-29 18:23 | 2026-06-25+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $34.10 | -1.00M | 18.68M | -5% | -$34.10M |
| DT | 2026-06-26 18:13 | 2026-06-24 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.81M | +12% | +$770.0K |
| DMT | 2026-06-26 18:13 | 2026-06-24 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $33.16 | -200.0K | 1.61M | -11% | -$6.63M |
| 2026-06-23 21:17 | 2026-06-20 | ROIV | Pulik Richard | CFO | F - Tax | $31.43 | -2,129 | 276.4K | -0.8% | -$66.9K | |
| 2026-06-23 21:16 | 2026-06-20 | ROIV | Humes Jennifer | CAO | F - Tax | $31.43 | -3,582 | 109.8K | -3% | -$112.6K | |
| DT | 2026-05-22 18:25 | 2026-05-20 | ROIV | Venker Eric | Pres, Immunovant CEO | F - Tax | $32.41 | -34.5K | 1.61M | -2% | -$1.12M |
| DT | 2026-05-22 18:25 | 2026-05-22 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.81M | +12% | +$770.0K |
| DT | 2026-05-22 18:25 | 2026-05-22 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $30.27 | -200.0K | 1.61M | -11% | -$6.05M |
| 2026-05-22 18:22 | 2026-05-20 | ROIV | Pulik Richard | CFO | F - Tax | $32.41 | -19.0K | 278.5K | -6% | -$614.6K | |
| DT | 2026-04-22 18:27 | 2026-04-20 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.85M | +12% | +$770.0K |
| DT | 2026-04-22 18:27 | 2026-04-20 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $29.59 | -200.0K | 1.65M | -11% | -$5.92M |
| D | 2026-04-22 18:26 | 2026-04-20 | ROIV | Pulik Richard | CFO | A - Grant | $0.00 | +60.6K | 297.5K | +26% | $0 |
| D | 2026-04-22 18:26 | 2026-04-20 | ROIV | Humes Jennifer | CAO | A - Grant | $0.00 | +29.2K | 113.4K | +35% | $0 |
| 2026-04-21 21:00 | 2026-04-17 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +896 | 120.3K | +0.8% | $0 | |
| 2026-04-21 21:00 | 2026-04-17 | ROIV | Oren Ilan | Dir | F - Tax | $29.83 | -95 | 120.2K | -0.1% | -$2,834 | |
| 2026-04-21 18:34 | 2026-04-17 | ROIV | Epperly Melissa B, | Dir | A - Grant | $0.00 | +670 | 16.5K | +4% | $0 | |
| 2026-04-21 18:32 | 2026-04-17 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +469 | 109.5K | +0.4% | $0 | |
| 2026-04-21 18:32 | 2026-04-17 | ROIV | MOMTAZEE JAMES C | Dir | F - Tax | $29.83 | -94 | 109.4K | -0.1% | -$2,804 | |
| 2026-04-20 18:27 | 2026-04-16 | ROIV | Gline Matthew | CEO, Dir | S - Sale | $29.16 | -289.8K | 16.74M | -2% | -$8.45M | |
| 2026-04-10 18:00 | 2026-04-08 | ROIV | Humes Jennifer | CAO | S - Sale | $28.37 | -13.5K | 84.2K | -14% | -$384.1K | |
| 2026-04-02 19:14 | 2026-03-31 | ROIV | Torti Frank | Pres, Vant COB | F - Tax | $27.70 | -160.0K | 13.58M | -1% | -$4.43M | |
| D | 2026-04-01 19:20 | 2026-03-30 | ROIV | Gline Matthew | CEO, Dir | M - OptEx | — | +97.3K | 17.38M | +0.6% | — |
| DM | 2026-04-01 19:20 | 2026-03-30+ | ROIV | Gline Matthew | CEO, Dir | F - Tax | $27.51 | -358.5K | 17.03M | -2% | -$9.86M |
| D | 2026-04-01 19:19 | 2026-03-30 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | — | +58.4K | 18.89M | +0.3% | — |
| DM | 2026-04-01 19:19 | 2026-03-30+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | F - Tax | $27.52 | -217.3K | 18.68M | -1% | -$5.98M |
| D | 2026-03-30 | 2026-03-26 | ROIV | Fitzgerald Meghan | Dir | M - OptEx | $8.80 | +70.0K | 113.0K | +163% | +$616.0K |
| D | 2026-03-30 | 2026-03-26 | ROIV | Fitzgerald Meghan | Dir | S - Sale+OE | $27.45 | -70.0K | 43.0K | -62% | -$1.92M |
| 2026-03-24 | 2026-03-20 | ROIV | Pulik Richard | CFO | F - Tax | $27.70 | -1,546 | 236.9K | -0.6% | -$42.8K | |
| 2026-03-24 | 2026-03-20 | ROIV | Humes Jennifer | CAO | F - Tax | $27.70 | -14.5K | 97.7K | -13% | -$402.4K | |
| D | 2026-03-19 | 2026-03-17 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $28.24 | -200.0K | 1.65M | -11% | -$5.65M |
| D | 2026-03-19 | 2026-03-17 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.85M | +12% | +$770.0K |
| 2026-03-18 | 2026-03-16 | ROIV | Epperly Melissa B, | Dir | S - Sale | $28.68 | -41.9K | 15.8K | -73% | -$1.20M | |
| 2026-02-24 | 2026-02-20 | ROIV | Venker Eric | Pres, Immunovant CEO | F - Tax | $27.15 | -7,051 | 1.65M | -0.4% | -$191.4K | |
| 2026-02-24 | 2026-02-20 | ROIV | Pulik Richard | CFO | F - Tax | $27.15 | -1,000 | 238.4K | -0.4% | -$27.1K | |
| DM | 2026-02-23 | 2026-02-19+ | ROIV | Torti Frank | Pres, Vant COB | M - OptEx | $3.85 | +3.00M | 14.75M | +26% | +$11.55M |
| DM | 2026-02-23 | 2026-02-19+ | ROIV | Torti Frank | Pres, Vant COB | S - Sale+OE | $27.35 | -3.00M | 13.74M | -18% | -$82.04M |
| D | 2026-02-18 | 2026-02-13 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $26.49 | -200.0K | 1.65M | -11% | -$5.30M |
| D | 2026-02-18 | 2026-02-13 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.85M | +12% | +$770.0K |
| MI | 2026-02-13 | 2026-02-11+ | ROIV | Gold Daniel Allen | Dir | S - Sale | $26.64 | -1.23M | 15.35M | -7% | -$32.66M |
| MI | 2026-02-13 | 2026-02-11+ | ROIV | MANCHESTER KEITH S | Dir | S - Sale | $26.64 | -1.23M | 15.13M | -7% | -$32.66M |
| MI | 2026-02-13 | 2026-02-11+ | ROIV | QVT Financial LP | Dir by Deputization | S - Sale | $26.64 | -1.23M | 15.35M | -7% | -$32.66M |
| D | 2026-02-11 | 2026-02-09 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $26.47 | -339.4K | 19.15M | -2% | -$8.99M |
| D | 2026-02-11 | 2026-02-09 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $12.68 | +651.6K | 19.49M | +3% | +$8.26M |
| D | 2026-02-11 | 2026-02-09 | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | J - Other | $26.47 | -312.1K | 18.84M | -2% | -$8.26M |
| 2026-01-22 | 2026-01-20 | ROIV | MOMTAZEE JAMES C | Dir | F - Tax | $22.98 | -122 | 109.0K | -0.1% | -$2,804 | |
| 2026-01-22 | 2026-01-20 | ROIV | MOMTAZEE JAMES C | Dir | A - Grant | $0.00 | +609 | 109.2K | +0.6% | $0 | |
| 2026-01-22 | 2026-01-20 | ROIV | Epperly Melissa B, | Dir | F - Tax | $22.98 | -54 | 57.7K | -0.1% | -$1,241 | |
| 2026-01-22 | 2026-01-20 | ROIV | Epperly Melissa B, | Dir | A - Grant | $0.00 | +815 | 57.7K | +1% | $0 | |
| 2026-01-22 | 2026-01-20 | ROIV | Oren Ilan | Dir | A - Grant | $0.00 | +1,164 | 119.6K | +1.0% | $0 | |
| 2026-01-22 | 2026-01-20 | ROIV | Oren Ilan | Dir | F - Tax | $22.98 | -124 | 119.4K | -0.1% | -$2,850 | |
| DT | 2026-01-14 | 2026-01-12 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $21.92 | -200.0K | 1.65M | -11% | -$4.38M |
| DT | 2026-01-14 | 2026-01-12 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.85M | +12% | +$770.0K |
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $21.72 | -1.33M | 20.27M | -6% | -$28.90M |
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | J - Other | $21.72 | -1.87M | 18.84M | -9% | -$40.55M |
| DM | 2025-12-31 | 2025-12-29+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $12.68 | +3.20M | 19.58M | +20% | +$40.55M |
| DM | 2025-12-29 | 2025-12-23+ | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $22.47 | -275.0K | 1.65M | -14% | -$6.18M |
| DM | 2025-12-29 | 2025-12-23+ | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +431.7K | 1.81M | +31% | +$1.66M |
| DM | 2025-12-29 | 2025-12-23 | ROIV | Pulik Richard | CFO | S - Sale+OE | $22.43 | -406.7K | 386.1K | -51% | -$9.12M |
Purchase Sale Sale after option exercise All abbreviations